T2 Biosystems (TTOO) Reaches $3.58 After 8.00% Up Move; Profile of 1 Analysts Covering MakeMyTrip Limited (MMYT)

June 20, 2017 - By Winifred Garcia

Among 4 analysts covering MakeMyTrip (NASDAQ:MMYT), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. MakeMyTrip had 7 analyst reports since August 12, 2015 according to SRatingsIntel. Deutsche Bank downgraded the shares of MMYT in report on Friday, October 30 to “Hold” rating. The firm has “Reduce” rating by Nomura given on Tuesday, February 23. The firm has “Neutral” rating by Nomura given on Friday, June 3. See MakeMyTrip Limited (NASDAQ:MMYT) latest ratings:

The stock of T2 Biosystems Inc (NASDAQ:TTOO) is a huge mover today! About 54,622 shares traded. T2 Biosystems Inc (NASDAQ:TTOO) has declined 60.66% since June 20, 2016 and is downtrending. It has underperformed by 77.36% the S&P500.The move comes after 5 months positive chart setup for the $110.16M company. It was reported on Jun, 20 by Barchart.com. We have $3.87 PT which if reached, will make NASDAQ:TTOO worth $8.81 million more.

Among 8 analysts covering T2 Biosystems Inc (NASDAQ:TTOO), 4 have Buy rating, 1 Sell and 3 Hold. Therefore 50% are positive. T2 Biosystems Inc had 14 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Underweight” rating by Morgan Stanley given on Wednesday, March 15. The stock of T2 Biosystems Inc (NASDAQ:TTOO) earned “Hold” rating by BTIG Research on Sunday, August 16. The firm earned “Buy” rating on Tuesday, August 2 by Canaccord Genuity. The firm has “Strong Buy” rating by WBB Securities given on Wednesday, July 20. As per Tuesday, October 27, the company rating was initiated by Canaccord Genuity. Janney Capital downgraded the shares of TTOO in report on Tuesday, April 12 to “Neutral” rating. BTIG Research initiated the stock with “Neutral” rating in Tuesday, July 21 report. Cantor Fitzgerald maintained T2 Biosystems Inc (NASDAQ:TTOO) rating on Wednesday, November 2. Cantor Fitzgerald has “Buy” rating and $9 target. Leerink Swann reinitiated T2 Biosystems Inc (NASDAQ:TTOO) on Thursday, November 10 with “Market Perform” rating. BTIG Research upgraded the shares of TTOO in report on Thursday, September 3 to “Buy” rating.

T2 Biosystems, Inc. is an in vitro diagnostics firm engaged in developing a technology platform offering an alternative to diagnostic methodologies. The company has market cap of $110.16 million. The Company’s T2 Magnetic Resonance platform enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). It currently has negative earnings. The Company’s initial development efforts target sepsis, hemostasis and Lyme disease.

Analysts await T2 Biosystems Inc (NASDAQ:TTOO) to report earnings on August, 7. They expect $-0.46 earnings per share, up 20.69% or $0.12 from last year’s $-0.58 per share. After $-0.48 actual earnings per share reported by T2 Biosystems Inc for the previous quarter, Wall Street now forecasts -4.17% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: